Kaiyuan securities released a research report on April 25, saying that it maintained the purchase rating of Yantai Dongcheng Biochemicals Co.Ltd(002675) ( Yantai Dongcheng Biochemicals Co.Ltd(002675) .sz, latest price: 10.12 yuan). The reasons for rating mainly include: 1) nuclear medicine industry: a golden track with good competition pattern, high entry barriers and large potential market space; 2) Many nuclear drug varieties have great potential, and heparin API can still contribute profits stably in the medium and long term. Risk tip: the new installation speed of PET-CT and the expansion speed of the company’s nuclear pharmacy are lower than expected; The progress of consistency evaluation of natroparin calcium was less than expected; The price of heparin raw materials fell.
AI comments: Yantai Dongcheng Biochemicals Co.Ltd(002675) in the past month, it has received the attention of one Research Report of securities companies and bought one.
